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Neuromuscular transmission and its pharmacological blockade
Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in
the intensive care unit
• Leo H.D.J. Booij
4.1 .Introduction
The response to muscle relaxants is, at the extremes 
of age, or in patients in the Intensive Care Unit, fre­
quently different from the response in younger adult 
patients and in the OR. This is on the one hand due to 
change in neuromuscular transmission and physio­
logical parameters in those patients, and on the other 
hand due to the existence of concurrent diseases and 
the use of medication.
4.2. M uscle relaxation at the extrem es of 
age
Immediately after birth the neuromuscular junction is 
still not completely matured, and thus the maturation 
process proceeds after birth. This results in a chang­
ing response to the administration of relaxants after 
birth until maturation is complete.
With old age, many physiological functions are 
altered, including hepatic and renal function. The 
pharmacokinetic behaviour of relaxants can thus 
change with age, ultimately leading to altered phar­
macodynamics.
4.2.1. Paediatric patients
Shortly after birth less acetylcholine is released from 
the prejunctional membrane than in adults. This is 
seen as spontaneous fade after tetanic and train-of- 
four stimulation. The post-junctional acetylcholine 
receptors have a different subunit structure, with 
more receptors located at the extrajunctional mem­
brane. These morphological differences have an 
effect on the action of the neuromuscular blocking 
agents, i.e. neonates are resistant to non-depolariz­
ers. Infants are usually, as susceptible for relaxants as 
young adults and children are resistant again (see 
Table 4,1).
Infants aged 1 month to 2 years, require a higher 
dose of suxamethonium than older children (> 2 
years) and adults because they have an excessive 
number of acetylcholine receptors. Suxamethonium 
leads to remarkedly fewer and less severe muscle fas- 
ciculations in children and also the incidence and 
severity of myalgia is lower. In some patients suxame­
thonium will lead to stiffness of the jaw, due to mas- 
seter muscle spasm [1]. This may lead to problems in 
endotracheal intubation, although in most cases 
relaxation occurs after 2 min [2]. There is no relation 
with other signs of hypermetabolism [3]. Jaw stiffness 
may be an early sign of malignant hyperthermia, but 
is not specific for it [4]. Others however state that a 
strong relationship exists [5].
Pharmacokinetic behaviour of non-depolarizing 
muscle relaxants is different in the various age groups 
of children. In neonates (birth to 2 months) and 
infants, there is frequently a decreased plasma clear­
ance and prolonged elimination half-life of neuro-
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The pharmacodynamic and pharmacokinetic characteristics 
of the non-depolarizing muscle relaxants are dependent on 
age. Thus differences are found between paediatric patients, 
adults, and elderly patients. Muscle relaxants cross the 
placenta and thus may cause problems in the fetus.
Many of the potential adverse effects of relaxant 
administration are seen more pronounced in intensive care 
patients. Prolonged effects and problems in weaning patients 
rorn the ventilator are observed when muscle relaxants are 
. used in such patients. Critical illness neuropathy is a 
syndrome different from relaxant induced-neuromyopathy, 
but may be enhanced by relaxant administration.
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Table 4.1 ED9S in mg/kg of non-depolarizing relaxants in infants, children, and adults
Infusion rate for maintenance of 95% block. All as rounded figures
Relaxant Infants Children Adults Maintenance 
infusion rate 
mg/kg/h in 
children
Alcuronium 0.195 0.270 0.220 0.110
Atracurium 0.240 0.330 0.210 0.530
Cisatracurium ** - - *»
Doxacurium 0.025 0.050 0.040 -
Mivacurium 0.130 0.140 0.080 0.950
Pancuronium 0.065 0.090 0.065 0.060
Pipecuronium 0.040 0.055 0.040 0.040
Rocuronium 0.255 0,400 0.350 0.595
Tubocurarine 0.410 0.500 0.480 **
Vecuronium 0.045 0.080 0.045 0.155
mg/kg) [13]. The pharmacokinetics of vecuronium is 
similar in children and adults [14]. Children are slight­
ly more sensitive to pipecuronium than adults; in 
infants its duration of action is shorter than both in 
children and adults [15]. For rocuronium the plasma 
clearance decreases with weight and age, and the 
VDss is similar in infants and adults [16].
muscular blocking agents (see Table 4.2). This can 
lead to prolonged paralysis.
The initial volume of distribution in children is larg­
er than in neonates and infants, leading to resistance 
to relaxants (see table 4.1). This has been demon­
strated for tubocurarine and atracurium [6-8]. With 
tubocurarine the VDss is higher in neonates. This cor­
relates with the larger extracellular volume in neo­
nates. Neonates and infants have a decreased plasma 
clearance and prolonged elimination half-life of tubo­
curarine. Part of this may be caused by immature 
renal function in neonates and small infants. The 
duration of action is not different.
Although there is a decrease in both volumes of 
distribution and plasma clearance in children, in one 
study the elimination half-life of atracurium was simi­
lar for infants, children and adults [9]. In another 
study, however, the same group of investigators 
found a prolonged elimination half-life and increased 
volume of distribution of atracurium in children [10].
In children the onset of doxacurium is more rapid, the 
duration is shorter, and there is a need for relatively 
higher doses of doxacurium than in adults [11 12]. In 
children mivacurium is less potent (ED95 0.10-0.11 nium, of which the durations of action also are pro-
4.2.2. Elderly patients
In elderly patients the number of motor units and the 
volume of the muscles is decreased. The decrease in 
plasma cholinesterase activity makes the elderly more 
sensitive to suxamethonium, and causes a prolonged 
effect. There is also a decrease in vital organ function 
and a change in body composition. The total body 
water is diminished and the amount of fat, relatively 
to the lean body mass, increased. As a result the vol­
umes of distribution and plasma clearance are 
decreased, leading to an increase in plasma relaxant 
concentration (see Table 4.1) [17-21]. Therefore the 
elderly are apparently more sensitive to the non­
depolarizing relaxants pancuronium, vecuronium, 
pipecuronium, tubocurarine, metocurine and alcuro-
Table 4.2 Pharmacokinetic data on muscle relaxants in relation to age, in adults, infants, and elderly
Relaxants VOss
d/kg)
C(P
(ml/kg/min )
V^zelim
(min)
Adults Infants Elderly Adults Infants Elderly Adults Infants Elderly
Alcuronium 0.32 0.32 0.37 1.3 « 0.53 200 440
Atracurium 0.20 0.21 0,10 6.6 7.7 5.30 21 20 22
Cisatracurium - - - m - - - -
Doxacurium 0.13 0.22 0.22 2.2 3.66 86 - 96
Gallamine 0.20 - 1.2 - - 134 - «1*
Metocurine 0.45 - 0.28 1.1 - 0.36 269 530
Mivacurium 0,11 - - 18.7 - 16.9 18 - V *
Pancuronium 0.20 0.21 0.32 1.8 1.7 1.19 150 103 170
Pipecuronium 0.31 - 0,39 2.5 - 2.4 154 - 181
Rocuronium 0.21 0.24 0.31 5.8 3.1 3.4 56 50 137
Tubocurarine 0.37 0.47 0.28 1.7 1.6 0.79 164 306 268
Vecuronium 0.27 0.32 0.18 5.2 5.7 3.6 71 65 58
longed [22-25]. A decrease in cardiac output and a 
longer circulation time in the elderly leads to a slower 
onset of action of the relaxants. Doxacurium, pipecu- 
ronium and rocuronium, however, do not seem to be 
affected by age [26-28]. Because atracurium is inde­
pendent of organ function, it is not affected by age. 
However, in the elderly a higher plasma concentra­
tion of the main metabolite laudanosine is found 
because of a decreased plasma clearance of this sub­
stance [31].
With pancuronium, tubocurarine, metocurine and 
vecuronium it was demonstrated that the concentra­
tion at which a certain degree of neuromuscular 
blockade exits is not different between elderly and 
younger adults. This indicates that there is no differ­
ence in receptor affinity for relaxants between these 
patients [32-35], For example, the dose-response 
relationship of the new relaxant rocuronium is not dif­
ferent in elderly and younger patients [36]. The block­
ade in the elderly, however, lasts longer and there is a 
slower onset compared to younger patients. The dif­
ferent effect, therefore, is completely due to a 
changed pharmacokinetic behaviour. An overview of 
the pharmacokinetic data on the relaxants in infants, 
adults, and elderly is given in Table 4.2.
The effect of neostigmine and pyridostigmine is 
prolonged in older patients, similar to the prolonged 
effect of non-depolarizing muscle relaxants (Table 
4.3) [37]. Although for edrophonium such an effect 
on the pharmacodynamics could not be demonstrat-
Table 4.3 Dose and duration of action of anti­
cholinesterase drugs in young and 
elderly patients
Anticholinesterase Duration 
(min)
Dose
(mg/kg)
Elderly Vbung
Edrophonium 1 2.2 1.3
Neostigmine 0.07 32 11
Pyridostigmine 0.14 35 14
ed, the clearance was decreased and the elimination 
half-life prolonged in the elderly [38].
The initial volume of distribution for neostigmine is 
larger in the elderly; for edrophonium there is no dif­
ference in distribution volume [39]. Based upon the 
results of these studies edrophonium should perhaps 
not been used in elderly patients.
4.3,Use of non-depolarizing relaxants dur­
ing pregnancy
During pregnancy there is, amongst others, an 
increase in total body water, and a fall in protein con­
centration and plasma cholinesterase activity. The 
liver and kidney function is also altered. This has an 
effect on the pharmacokinetic and pharmacodynam­
ics of the non-depolarizing relaxants. In the pregnant 
female, the plasma clearance of pancuronium is larg­
er, and the elimination half-life is shorter than in the 
non-pregnant female [40 41]. During pregnancy
there is transfer of muscle relaxants administered to 
the mother across the pfacenta to the fetus. 
Transplacental transfer can be expressed as a ratio 
between the maternal and umbilical vein concentra­
tion [42-44]. Suxamethonium has a foetal : maternal 
ratio of 0.3, the transfer ratio of non-depolarizers is 
smaller (see Table 4.4). Since neonates are more 
resistant to relaxants than adults, the concentration of 
relaxants in the foetus has no detectable effects when 
normal clinical doses are administered to the mother.
Magnesium sulphate and phenytoin, used for the
Table 4.4 Transplacental transfer o f muscle
relaxants,
UV = umbilical vein concentration,
MV  = maternal venous concentration
Relaxant UV/UM
Suxamethonium 0.30
Alcuronium 0.26
Atracurium 0.12
Cisatracurium »
Metocurine 0.21
Pancuronium 0.21
Rocuronium 0,16
Vecuronium 0.11
treatment of pre-eclampsia, interfere with neuromus­
cular transmission. They respectively increase the sen­
sitivity and cause resistance for non-depolarizers. 
During pregnancy the plasma cholinesterase activity 
decreases. It remains lowered until approximately 2 
months after delivery [45], This leads to increased 
sensitivity for, and prolonged effect of, suxamethoni­
um. Pregnant patients also have a lower incidence of 
myalgia after suxamethonium administration.
4.4.The use of m u scle  relaxants in the 
intensive care unit
The first actual use of muscle relaxants in humans was 
in an "Intensive Care' situation, when West in 1932 
administered curare to a patient with tetanus [46]. In 
the past almost every patient on artificial ventilation 
in the ICU received muscle relaxants. After the disad­
vantages of the use of relaxants, i.e. occurrence of dis­
connections, inability to cough and sigh (atelectasis 
formation), difficulties in neurological assessment, 
occurrence of awareness and thrombo-emboiism, 
masking of signs as motion and defence, and devel­
opment of disuse atrophy, were recognized, they are 
only administered on indication. Other disadvantages 
are that patients appear to be more prone to nosoco­
mial infections, especially when they are treated with 
antibiotics and H2-blockers, and that careless posi­
tioning of patients may lead to peripheral nervous 
damage. Also it is now well recognized that relaxants 
can have dangerous side-effects such as haemody- 
namic changes and histamine release. Drug interac­
tions with muscle relaxants are also frequent in the 
ICU.
In 1981 it was stated that in 90% of the ICUs mus­
cle relaxants were routinely administered to patients
for 'sedation' [47]. In 1987 this was still practice in 
20% of the ICUs [48]. Recently it was stated that in 
the USA approximately 9% of all ICU patients receive 
a relaxant, I.e. 27% pancuronium, 56% vecuronium 
and 17% atracurium. Patients receiving relaxants 
have a higher APACHE II score (24 versus 11) than 
patients not receiving relaxants, and their mortality is 
51% [49]. It is believed that in Europe an even more 
restricted policy for the prescription of muscle relax­
ants is present.
Currently indications for the use of muscle relax­
ants in the ICU are considered for the prevention of 
extremely high airway pressure, to obtain decrease in 
oxygen consumption, to abolish muscle rigidity (teta­
nus), to cut epileptic status, to decrease intracranial 
pressure (ICP), and to facilitate procedures as MRI, 
CT-scanning and endoscopy [50], It must be remem­
bered that relaxants do not provide sedation and/or 
analgesia, and thus they should always be adminis­
tered in combination with sedatives/hypnotics and, 
when needed, analgesics [51].
4.4.1. Adverse effects of muscle relaxants in ICU 
patients
It is now realized that the administration of muscle 
relaxants in ICU patients is not without risk. Muscle 
relaxants were originally developed and tested for rel­
atively short-du ration administration. Nowadays, 
relaxants are sometimes used continuously for several 
weeks in the ICU. It is therefore not surprising that 
strange effects are reported in many cases.
The response to muscle relaxants, both in anaes­
thesia and intensive care patients, is highly variable. 
Although in general short-acting drugs are used in 
the ICU, long duration effects have been observed, 
not only with relaxants, but also with either sedatives 
(midazolam, propofol, etc.) or opioids (fentanyl, 
alfentanil, etc.). The main reason is primarily a change 
in pharmacokinetic behaviour of these compounds in 
sick patients as compared to young and 'normal' 
patients, where the original studies on the pharma­
cokinetics of the drugs were performed. Also pharma­
codynamic factors are involved in this variability. Of 
course there is a strong relationship between pharma­
cokinetic and pharmacodynamic factors. Disturbed 
renal and hepatic function [52], the presence of other 
concurrent diseases [53] and interaction with simulta­
neously administered drugs are amongst these factors 
[54].
4.4. h h  Tachyphylaxis (resistance) to non-depolariz­
ers
Problems with relaxation in the ICU are frequently the 
result of the side-effects of the relaxants, i.e. cardio­
vascular effects, histamine release, muscarinic effects.
When non-depolarizers are administered for a 
longer period of time, tachyphylaxis frequently devel­
ops. This is thought to be caused by receptor up- 
regulation, and is seen both in adult and paediatric 
patients, and has been confirmed in ICU patients [55 
56]. Such results were also reached in animal studies 
[57]. Development of resistance has been demon­
strated with pancuronium, vecuronium and atracuri­
um [58-62].
4.4.1.2. Cardiovascular effects of relaxants in ICU 
patients
Most muscle relaxants have cardiovascular effects, 
which, especially in ICU patients, are unwanted. 
Suxamethonium causes increased peripheral vascular 
resistance and bradycardia. Pancuronium triggers 
sympathetic discharge with hypertension and left 
ventricular failure, it affects cardiac muscarinic recep­
tors, and promotes release and blocks reuptake of 
noradrenaline. These cardiovascular effects may be 
more pronounced in patients receiving aminophylline 
or catecholamines. The cardiovascular effects from 
pancuronium (tachycardia, hypertension) are very 
dangerous in patients with aortic stenosis [63]. 
Tubocurarine and to a lesser extent alcuronium causes 
vasodilatation, partly by histamine release. The hista­
mine-releasing properties are shared with most ben- 
zylisoquinolines. Doxacurium and pipecuronium are 
free from cardiovascular effects [64].
4.4.13. Respiratory effects of relaxants 
All muscle relaxants inherently have the potential risk 
of interference with respiratory function because they 
all paralyse skeletal muscles. If artificial ventilation is 
insufficient, this may lead to permanent damage. 
Residual paralysis not only carries the risk of respirato­
ry depression but also decreases the ability to cough 
or sigh and to transport mucus, thus development of 
atelectasis is more likely to occur.
Muscle relaxants can, at least theoretically, influ­
ence airway tone. The first reason is histamine release, 
which may potentially cause constriction of the air­
ways [66-67]. The second is that relaxants can act on 
muscarinic receptors in airway smooth muscles [68]. 
It has been demonstrated that d-tubocurarine and 
atracurium significantly increase airway muscle tone 
[69 70]. Others were unable to demonstrate such 
effects [71 72].
Another possible effect of muscle relaxants is on 
the hypoxic ventilatory response. It has been demon­
strated that in partial vecuronium-induced neuromus­
cular blockade inhibition of the carotid body hypoxic 
chemosensitivity occurs [73]. Whether also other 
relaxants have this effect and what the clinical impli­
cations are, is still unclear.
4.4.1 A. Accumuiation of relaxants and prolonqed 
effect
After short administration of drugs, its effect usually 
terminates when the plasma concentration decreases 
from redistribution of the drugs. After prolonged 
administration, when the stores are filled up, meta­
bolism and excretion become more important.
Many relaxants are excreted in urine and bile, and 
thus accumulate in patients with renal or hepatic fail­
ure. Pharmacogenetic abnormalties have been dem­
onstrated in the population for a variety of drugs, 
they are not important for redistribution as limiting 
factor but, they are important when the drug is 
dependent on metabolism and excretion [74], In the 
ICU drugs are generally administered over a long 
time, and a different pharmacokinetic behaviour, as 
compared to short-term administration, can be 
expected.
There are only few data available on the pharma­
cokinetic behaviour of muscle relaxants in ICU 
patients. One of the limitations for such studies is the
variability in diseases and drugs coadministered in 
such patients. This variability will disturb the results of 
the studies and only produce information that is not 
generally applicable.
About 50% of patients receiving vecuronium over a 
long period of time developed prolonged paralysis. 
All these patients had renal insufficiency, and about 
half also had hepatic dysfunction. Most patients 
developing prolonged paralysis were female and had 
a metabolic acidosis. All had a higher plasma concen­
tration of 3-desacetyl-vecuronium compared with the 
patients not experiencing prolonged paralysis [75- 
77]. For this compound a storage compartment is 
likely to exist. With pancuronium active metabolites 
may also accumulate [78].
Only atracurium and mivacurium are independent 
from organ function. Prolonged administration of 
atracurium can also lead to prolonged muscle weak­
ness [79].
4.4.7.5. Central nervous system effects of relaxants 
There is a possibility that muscle relaxants after long 
administration can reach considerable concentrations 
in this brain, and interfere with cerebral acetylcholine 
receptors. This is especially a possibility to consider in 
patients with disturbed blood-brains barriers (either 
from disease or from the administration of mannitol 
and other hyperosmolar fluids). It is well known that 
non-depolarizers have an excitatory central nervous 
system effect with myotonia, convulsions and auto­
nomic changes [80 81]. Presence of relaxants in CSF 
has been demonstrated after administration of large 
doses [82]. Suxamethonium is known to increase 
intracranial pressure and may lead to potassium 
release in brain-injured patients [83].
4.4.1.6. Muscle weakness and problems in weaning 
from artificial ventilation
Recently muscle areflexta, atrophy and sensory 
impairment in patients with multi-organ failure have 
been attributed to the prolonged administration of 
muscle relaxant [84 85]. Muscle weakness may delay 
weaning from artificial ventilation, and can last for 
several months. In one study 50% of the patients in 
the ICU developed polyneuropathy after long dura­
tion administration of vecuronium [86]. However, 
such signs of polyneuropathy were also observed in 
patients not receiving muscle relaxants [87], This syn­
drome was called critical illness polyneuropathy (CIP). 
The signs are weakness of the limbs, absence of deep 
tendon reflexes, and difficulty in weaning patients 
from the ventilator. In another study, up to 70% of all 
ICU patients with sepsis and multiple organ failure 
had symptoms of this syndrome [88 89]. In 50% of 
the patients with the syndrome, muscle fibre necrosis 
typical for denervation has been seen, suggesting 
that myopathy is also present [90], Apart from motor 
function deficits sensory deficits can occur. EMG read­
ings in patients with CIP do not demonstrate neuro­
muscular transmission disorders [91]. This suggests 
that the problem is more a myopathy than a neuropa­
thy. The situation improves when sepsis is controlled. 
The neuropathy after administration of relaxants in 
ICU patients is a different entity. It is usually symmetri­
cal, and does not usually involve the sensory system. 
Neuromuscular transmission is also affected. EMG 
readings frequently resemble those changes seen in
Guillain-Barre syndrome or myonecrosis, but can also 
resemble readings resulting from residual neuromus­
cular blockade, I.e. the neuromuscular transmission is 
disturbed in these situations. Only motor fibres are 
involved. In most patients the creatinine phosphoki- 
nase and aldolase levels are elevated [92]. Muscle 
biopsies show loss of structure centrally in muscfe 
fibres, and loss of myosin [93 94]. Changes in mito­
chondria were also observed [99].
The long-term administration of corticosteroids 
may also potentiate the problem of long-term muscle 
weakness [96-98]. Aminogycosides have also been 
connected with the development of prolonged mus­
cle weakness. The muscle weakness usually resolves 
slowly over weeks or even months after stopping the 
relaxants. Prolonged weakness after long-term relax­
ant administration has been confirmed by others 
[99]. Some have related the development of the syn­
drome to the dose of the relaxant administered, i.e. in 
adults pancuronium excessive to 24 mg/day [100]. 
Further studies are needed to evaluate these neuro­
pathic and myopathic effects. The combination of 
steroidal-based relaxants and corticosteroids, espe­
cially in patients with renal failure, appears to increase 
the change of prolonged block [101]. However, it 
must be realised that the relaxants with a steroidal 
structure are more frequently used in the ICU than 
the benzylisoquinolines, However, prolonged weak­
ness with atracurium has also been described [102]. 
The syndrome is different from the muscle weakness 
occurring during prolonged treatment with high 
doses corticosteroids [103], in this last syndrome the 
proximal limb muscles are involved, and the respira­
tory muscles are spared.
It is not clear whether the weakness is the result of 
a direct toxic relaxant effect, or is the result of neuro­
muscular transmission inactivity.
4.4.1.7. Is atracurium, because of laudanosine, con­
traindicated in the ICU?
In ICU patients, laudanosine, the major metabolite of 
atracurium, may accumulate both in plasma and in 
cerebrospinal fluid [104], This metabolite is also seen 
at higher concentrations in patients with renal and 
hepatic disease. In animal experiments, laudanosine 
causes seizures. This, however, has not been shown in 
patients [105]. In vitro studies in isolated rat hepato- 
cytes have demonstrated that another metabolite of 
atracurium, a monoacrylate, causes alkylation of 
endogenous nucleophiles, resulting in cell damage 
[108]. This effect seems to be negligible in humans. 
Long-term use of atracurium in ICU patients does 
seem to be safe, but care is needed when using high 
doses fora long time.
4.4.2. Methods of relaxant administration in ICU 
patients
It is advisable to regularly monitor the degree of 
neuromuscular blockade when relaxants are admin­
istered for a long period [107]. There is, in most situ­
ations, no need to completely abolish the response 
to peripheral nerve stimulation, but a remaining of 
1-2 responses to train-of-four stimulation, or a 10- 
20% remaining contraction force in single twitch 
stimulation provides sufficient relaxation. The short­
er acting relaxants are preferably used to guarantee 
a faster recovery upon discontinuation of the block­
ade. They are favourably administered by continu­
ous infusion for reasons of constant blockade and 
labour intensivity. When relatively short lasting 
relaxation is needed intermittent dose administra­
tion is of course, an option. Interaction with con­
comitantly administered drugs (antibiotics, seda­
tives) should be anticipated.
4.4.3. Suxamethonium in ICU patients
Suxamethonium is, due to its fast onset and short 
duration, frequently used to facilitate intubation in 
ICU patients. However, it must be considered that this 
may lead to increased potassium release and subse­
quent cardiac arrest. This is seen in patients where 
proliferation of extrajunctional acetylcholine recep­
tors has occurred, i.e. crush injuries, bums, denervat- 
ing diseases [108]. It is also seen in patients with intra- 
abdominal infections, and prolonged immobilization. 
Through muscarinic effects suxamethonium can lead 
to bradycardia, arrhythmia, and increased intracranial 
pressure. Prolonged administration leads to conver­
sion of a depolarizing blockade into a phase II block. 
When decrease in plasma cholinesterase activity 
exists, a prolonged effect of suxamethonium is seen. 
In the last situation fresh frozen plasma will reverse 
the blockade [109],
4.4.4. Denervation and burn injuries
In burn trauma there is up-regulation of acetylcholi- 
nereceptors. This results in hypersensitivity and 
hyperkalemia after suxamethonium administration. It 
also results in resistance to non-depolarizing relax- 
ants, starting around day 5 post-burn, reaching a 
maximum effect around day 30 and persisting for up 
to 2 years [110]. Similar phenomena develop after 
denervation, starting around the third day [111].
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